Exelixis
↗Alameda, USA
Exelixis is a leading oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. The company is best known for its flagship product, CABOMETYX (cabozantinib), a multi-kinase inhibitor that has become a standard of care in several oncology indications.
Beyond its commercial success, Exelixis is aggressively expanding its pipeline through internal research and strategic collaborations. The company is focused on next-generation modalities, including antibody-drug conjugates (ADCs) and bispecific antibodies, aiming to build a multi-franchise oncology portfolio that addresses significant unmet medical needs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$2.32B
Founded:1994
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
Total Raised:$118M
Investors:Symphony Evolution, GlaxoSmithKline (GSK)
STOCK
Exchange:NASDAQ
Ticker:EXEL
Market Cap:$11.4B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (CABOMETYX); NDA Accepted (Zanzalintinib)
Modalities:Small molecule, ADC, Bispecific antibody
Active Trials:50
Trial Phases:Phase 1: 12 | Phase 2: 25 | Phase 3: 10 | Phase 4: 3
FDA Approvals:3
EMA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:Exelixis Plant Sciences (formerly)
Key Partnerships:Ipsen (Commercialization outside US/Japan), Takeda (Commercialization in Japan), Roche/Genentech (COTELLIC and combination trials), Merck (Clinical trial collaborations), Bristol Myers Squibb (Combination trials)
COMPETITION
Position:Leader
Competitors:Pfizer, Merck & Co., Novartis, Bristol Myers Squibb, Agios Pharmaceuticals
LEADERSHIP
Key Executives:
Michael M. Morrissey, Ph.D. - President and CEO
Christopher J. Senner - EVP and CFO
Dana T. Aftab, Ph.D. - EVP, Research and Development
Scientific Founders:Spyridon Artavanis-Tsakonas, Corey Goodman, Gerry Rubin
Board Members:Stelios Papadopoulos (Chair), Maria C. Freire, George Poste, Julie Anne Smith
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Exelixis. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.